Forecast

The analysts' average price target is +92,93€ (−24,06%). The median is +105,12€ (−14,10%).

Buy	8
Hold	16
Sell	4

News Go to news feed

FDA approves Moderna vaccines for 2026–2027 COVID-19 season

The FDA has approved supplemental applications for Moderna’s adapted COVID-19 vaccines Spikevax and mNEXSPIKE for the 2026–2027 season. Both formulations are monovalent and targeted at the XFG subvariant of the JN.1 lineage; Spikevax is authorized for people from 6 months with risk factors and all those 65 and older, while mNEXSPIKE is authorized for people 12 to 64 with risk factors and all those 65 and older. Moderna expects the updated vaccines to be available in the coming days; the formulations have already received approvals in several countries and are under review worldwide. The company notes possible side effects including myocarditis/pericarditis in young men as well as common vaccine reactions. » More on de.investing.com
Moderna: $10,000 investment a year ago would have grown to $59,625.50 (+496.25%)

If $10,000 had been invested in Moderna a year ago (closing price $25.10), the 398.406 shares held on August 26, 2026, at a closing price of $149.66 would be worth $59,625.50, a performance of +496.25%. Moderna is most recently valued at about $63.41 billion. Stock splits and dividends are not included in the calculation. » More on finanzen.net
Moderna plans issuance of $2 billion convertible notes due 2032

Moderna announced a private placement of senior, unsecured convertible notes with an aggregate principal amount of $2.0 billion maturing in 2032, with a 13-day greenshoe option of up to $300 million. The notes pay no ongoing interest; upon conversion Moderna may, at its option, settle in cash, shares or a combination. Net proceeds are intended for capped-call transactions and general corporate purposes, including expansion of its oncology business and debt reduction. The capped-call transactions are intended to mitigate dilution; the initial cap price will be at least 150% above the last closing price on the pricing date. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Moderna Inc. has already paid 0,17€ in dividends. The last payout was in May 2022.

Financials

In the last quarter, Moderna Inc. had revenue of 127.05m€ and net profit of −685.20m€

(EUR)	Jun 2026	YoY
Revenue	+127.05m	5,46%
Gross profit	+45.56m	133,49%
Net profit	−685.20m	2,11%
EBITDA	−616.85m	4,33%

Fundamentals

Metric	Value
Market capitalization	+54.08b€
Number of shares	396.79m
52-week high/low	+151,59€ - +19,12€
Dividends	No
Beta	0,9
P/E ratio	−19,90
PEG ratio	+2,36
P/B ratio	+9,30
P/S ratio	+28,29

Company profile

Moderna, Inc., ein Biotechnologieunternehmen, entdeckt, entwickelt und vermarktet Boten-RNA-Therapeutika und Impfstoffe zur Behandlung von Infektionskrankheiten, Immunonkologie, seltenen Krankheiten, Herz-Kreislauf-Erkrankungen und Autoimmunerkrankungen in den Vereinigten Staaten, Europa und international. Die Impfstoffe gegen Atemwegserkrankungen umfassen COVID-19, Grippe, Respiratory Syncytial Virus, Endemic HCoV und hMPV+PIV3; die latenten Impfstoffe umfassen Cytomegalovirus, Epstein-Barr-Virus, Humanes Immundefizienz-Virus, Herpes-Simplex-Virus und Varizella-Zoster-Virus; und die Impfstoffe für die öffentliche Gesundheit bestehen aus Zika- und Nipah-Impfstoffen. Das Unternehmen bietet auch systemische sekretorische und Zelloberflächentherapeutika, Krebsimpfstoffe wie personalisierte Krebs-, KRAS- und Checkpoint-Impfstoffe, intratumorale Immuno-Onkologieprodukte, lokalisierte regenerative, systemische intrazelluläre und inhalative pulmonale Therapeutika an. Das Unternehmen unterhält strategische Allianzen mit AstraZeneca PLC, Merck & Co, Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc; Metagenomi, Inc; der Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; und der Bill & Melinda Gates Foundation sowie eine Kooperations- und Lizenzvereinbarung mit Chiesi Farmaceutici S.P.A. Das Unternehmen war früher als Moderna Therapeutics, Inc. bekannt und änderte im August 2018 seinen Namen in Moderna, Inc. Moderna, Inc. wurde im Jahr 2010 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.

Name	Moderna Inc.
CEO	Stéphane Bancel
Headquarters	Cambridge, ma USA
Website	investors.modernatx.com/overview/default.aspx
Sector	Health Care
Industry	Biotechnology
IPO	12/07/2018
Employees	4.700